Literature DB >> 20737633

Biodegradable nanoparticles with sustained release of functional siRNA in skin.

Gunilla B Jacobson1, Emilio Gonzalez-Gonzalez, Ryan Spitler, Rajesh Shinde, Devin Leake, Roger L Kaspar, Christopher H Contag, Richard N Zare.   

Abstract

A key challenge in developing RNAi-based therapeutics is efficient delivery of functional short interfering RNA (siRNA) to target cells. To address this need, we have used a supercritical CO(2) process to incorporate siRNA in biodegradable polymer nanoparticles (NPs) for in vivo sustained release. By this means we have obtained complete encapsulation of the siRNA with minimal initial burst effect from the surface of the NPs. The slow release of a fluorescently labeled siRNA mimic (siGLO Red) was observed for up to 80 days in vivo after intradermal injection into mouse footpads. In vivo gene silencing experiments were also performed, showing reduction of GFP signal in the epidermis of a reporter transgenic mouse model, which demonstrates that the siRNA retained activity following release from the polymer NPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20737633     DOI: 10.1002/jps.22147

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  In vivo sustained release of siRNA from solid lipid nanoparticles.

Authors:  Tatsiana Lobovkina; Gunilla B Jacobson; Emilio Gonzalez-Gonzalez; Robyn P Hickerson; Devin Leake; Roger L Kaspar; Christopher H Contag; Richard N Zare
Journal:  ACS Nano       Date:  2011-11-18       Impact factor: 15.881

2.  siRNA-based spherical nucleic acids reverse impaired wound healing in diabetic mice by ganglioside GM3 synthase knockdown.

Authors:  Pratik S Randeria; Mark A Seeger; Xiao-Qi Wang; Heather Wilson; Desmond Shipp; Chad A Mirkin; Amy S Paller
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

Review 3.  Upconversion nanoparticles: design, nanochemistry, and applications in theranostics.

Authors:  Guanying Chen; Hailong Qiu; Paras N Prasad; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2014-03-10       Impact factor: 60.622

Review 4.  Molecular imaging with theranostic nanoparticles.

Authors:  Jesse V Jokerst; Sanjiv S Gambhir
Journal:  Acc Chem Res       Date:  2011-09-15       Impact factor: 22.384

Review 5.  Nanoparticle PEGylation for imaging and therapy.

Authors:  Jesse V Jokerst; Tatsiana Lobovkina; Richard N Zare; Sanjiv S Gambhir
Journal:  Nanomedicine (Lond)       Date:  2011-06       Impact factor: 5.307

6.  Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.

Authors:  Jingga Morry; Worapol Ngamcherdtrakul; Shenda Gu; Shaun M Goodyear; David J Castro; Moataz M Reda; Thanapon Sangvanich; Wassana Yantasee
Journal:  Biomaterials       Date:  2015-07-10       Impact factor: 12.479

Review 7.  Organic dots (O-dots) for theranostic applications: preparation and surface engineering.

Authors:  Amin Shiralizadeh Dezfuli; Elmira Kohan; Sepand Tehrani Fateh; Neda Alimirzaei; Hamidreza Arzaghi; Michael R Hamblin
Journal:  RSC Adv       Date:  2021-01-11       Impact factor: 3.361

Review 8.  Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses.

Authors:  Panoraia I Siafaka; Neslihan Üstündağ Okur; Evangelos Karavas; Dimitrios N Bikiaris
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

9.  RNA interference for the treatment of papillomavirus disease.

Authors:  Richa Singhania; Norliana Khairuddin; Daniel Clarke; Nigel Aj McMillan
Journal:  Open Virol J       Date:  2012-12-28

10.  Development of novel anti-Kv 11.1 antibody-conjugated PEG-TiO2 nanoparticles for targeting pancreatic ductal adenocarcinoma cells.

Authors:  Angelica Sette; Jolanda Spadavecchia; Jessem Landoulsi; Sandra Casale; Bernard Haye; Olivia Crociani; Annarosa Arcangeli
Journal:  J Nanopart Res       Date:  2013-11-16       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.